ECSP077984A - Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina - Google Patents

Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina

Info

Publication number
ECSP077984A
ECSP077984A EC2007007984A ECSP077984A ECSP077984A EC SP077984 A ECSP077984 A EC SP077984A EC 2007007984 A EC2007007984 A EC 2007007984A EC SP077984 A ECSP077984 A EC SP077984A EC SP077984 A ECSP077984 A EC SP077984A
Authority
EC
Ecuador
Prior art keywords
formulation
tienopiridine
aggregation inhibitor
plate aggregation
plate
Prior art date
Application number
EC2007007984A
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP077984A publication Critical patent/ECSP077984A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invención se refiere a la formulación de un compuesto de fórmula Iproceso de manufactura y métodos para usarlos.
EC2007007984A 2005-06-10 2007-12-07 Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina ECSP077984A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
ECSP077984A true ECSP077984A (es) 2008-01-23

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007984A ECSP077984A (es) 2005-06-10 2007-12-07 Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina

Country Status (34)

Country Link
US (1) US20080176893A1 (es)
EP (1) EP1896019B1 (es)
JP (1) JP2008543755A (es)
KR (2) KR20080008413A (es)
CN (1) CN101193633B (es)
AR (1) AR054283A1 (es)
AT (1) ATE441413T1 (es)
AU (1) AU2006258102B2 (es)
BR (1) BRPI0611350B8 (es)
CA (1) CA2611668C (es)
CY (1) CY1109502T1 (es)
DE (1) DE602006008942D1 (es)
DK (1) DK1896019T3 (es)
DO (1) DOP2006000126A (es)
EA (1) EA011693B1 (es)
EC (1) ECSP077984A (es)
ES (1) ES2330373T3 (es)
HR (1) HRP20090516T1 (es)
IL (1) IL187830A0 (es)
MA (1) MA29688B1 (es)
MX (1) MX2007015431A (es)
MY (1) MY151038A (es)
NO (1) NO20076317L (es)
NZ (1) NZ564003A (es)
PE (1) PE20070320A1 (es)
PL (1) PL1896019T3 (es)
PT (1) PT1896019E (es)
RS (1) RS51194B (es)
SI (1) SI1896019T1 (es)
TN (1) TNSN07466A1 (es)
TW (1) TWI318571B (es)
UA (1) UA91051C2 (es)
WO (1) WO2006135605A2 (es)
ZA (1) ZA200710697B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd PREPARATION WITH FILM COVER AND IMPROVED STABILITY
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
WO2008072533A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 固形製剤の製造方法
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
KR101505212B1 (ko) * 2007-03-02 2015-03-23 다이이찌 산쿄 가부시키가이샤 고순도 프라수그렐염산염의 제조 방법
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009098142A1 (en) * 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
ES2353853T3 (es) 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
WO2010132711A1 (en) * 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HU227746B1 (en) * 2000-07-06 2012-02-28 Ube Industries Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
PT1653930E (pt) * 2003-08-05 2008-03-12 Zentiva As Métodos para a estabilização da atorvastatina

Also Published As

Publication number Publication date
KR20100076050A (ko) 2010-07-05
AU2006258102B2 (en) 2011-09-15
WO2006135605A3 (en) 2007-04-12
EP1896019B1 (en) 2009-09-02
EP1896019A2 (en) 2008-03-12
NO20076317L (no) 2008-02-29
HRP20090516T1 (hr) 2009-10-31
NZ564003A (en) 2011-07-29
WO2006135605A2 (en) 2006-12-21
ATE441413T1 (de) 2009-09-15
TWI318571B (en) 2009-12-21
MY151038A (en) 2014-03-31
ES2330373T3 (es) 2009-12-09
DOP2006000126A (es) 2006-12-15
TNSN07466A1 (en) 2009-03-17
ZA200710697B (en) 2009-08-26
US20080176893A1 (en) 2008-07-24
IL187830A0 (en) 2008-04-13
BRPI0611350A2 (pt) 2010-12-07
SI1896019T1 (sl) 2010-01-29
BRPI0611350B1 (pt) 2020-09-15
KR20080008413A (ko) 2008-01-23
CN101193633B (zh) 2011-12-14
RS51194B (sr) 2010-10-31
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
AU2006258102A1 (en) 2006-12-21
EA200702670A1 (ru) 2008-04-28
MA29688B1 (fr) 2008-08-01
PL1896019T3 (pl) 2010-01-29
CN101193633A (zh) 2008-06-04
CY1109502T1 (el) 2014-08-13
DE602006008942D1 (en) 2009-10-15
PT1896019E (pt) 2009-11-19
CA2611668C (en) 2013-10-15
MX2007015431A (es) 2008-02-21
UA91051C2 (ru) 2010-06-25
PE20070320A1 (es) 2007-05-12
AR054283A1 (es) 2007-06-13
JP2008543755A (ja) 2008-12-04
BRPI0611350B8 (pt) 2021-05-25
DK1896019T3 (da) 2009-10-26
HK1116422A1 (en) 2008-12-24
TW200718420A (en) 2007-05-16

Similar Documents

Publication Publication Date Title
ECSP077984A (es) Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina
AR065136A1 (es) Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
UY32049A (es) Inhibidores de cmet
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
DOP2009000039A (es) COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka
NO20080761L (no) Acykliske Ikur inhibitorer
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
CR10157A (es) Compuestos químicos
ATE542798T1 (de) Organische verbindungen
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ECSP10010192A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
UY30185A1 (es) Método para la producción preferencial de isómeros geométricos y método de aislamiento
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
EA200870038A1 (ru) Способ получения аминов
UY31398A1 (es) Proceso para sintetizar compuestos de ácido fosfónico y posfínico
GT200600102A (es) Procedimiento para la preparacion de compuestos benzoxazol sustituidos
CR9573A (es) Formulacion mejorada de un inhibidor de agregacion de plaquetas de tienopiridina
UY28828A1 (es) Nueva forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s, 6s-2,8-diazabiciclo(4.3.0)nonan-8-il)-6-fluoro-1,4-dihidro-4-oxo-3-quinolincarboxílico
UY30648A1 (es) Formas salinas de compuestos de benzotienilo sustituido